1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Q32 Bio Inc.

Q32 Bio Inc.

QTTB
Q32 Bio Inc.US flagNASDAQ Global Market
7.79
USD
+0.27
- -
231.90MMarket Cap

Total Valuation

Q32 Bio Inc. carries a market capitalization of 231.90M, placing it among publicly traded companies globally. Its enterprise value stands at 201.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap231.90M
Enterprise Value201.43M

Share Statistics

Q32 Bio Inc. currently has 23.74M shares outstanding.

Shares Outstanding23.74M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Q32 Bio Inc. trades at a trailing price-to-earnings ratio of 5.87. The price-to-sales ratio is 3.69, and the price-to-book ratio stands at 2.86.

PE Ratio5.87
PS Ratio3.69
PB Ratio2.86
P/TBV Ratio2.86
P/FCF Ratio-10.00
P/OCF Ratio-10.00

Enterprise Valuation

The EV/Sales ratio of 3.75 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 9.39 provides insight into valuation relative to core operating earnings.

EV / Sales3.75
EV / EBITDA9.23
EV / EBIT9.39
EV / FCFN/A

Financial Position

Q32 Bio Inc. maintains a current ratio of 20.30, meaning it holds 20.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.00, indicating elevated leverage, while an interest coverage ratio of 43.64 demonstrates strong ability to service its debt obligations.

Current Ratio20.30
Quick Ratio20.12
Debt / Equity5.00
Debt / EBITDA0.24
Interest Coverage43.64

Financial Efficiency

Q32 Bio Inc. posts a return on equity of 125.06 and a return on invested capital of 36.48.

Return on Equity (ROE)125.06
Return on Assets (ROA)37.13
Return on Invested Capital (ROIC)36.48
Return on Capital Employed (ROCE)58.28
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Stock Price Statistics

Q32 Bio Inc.'s stock has gained approximately 133.93393% over the past 52 weeks. The 50-day moving average sits at 11.67, while the 200-day moving average is 9.00.

Beta (5Y)N/A
52-Week Price Change133.93393%
50-Day Moving Average11.67
200-Day Moving Average9.00
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Q32 Bio Inc. generated 53.74M in revenue and converted that into 33.79M in net income, yielding earnings per share of 2.17. EBITDA reached 21.82M, while operating income came in at 21.46M.

Revenue53.74M
Gross ProfitN/A
Operating Income21.46M
Pretax Income33.79M
Net Income33.79M
EBITDA21.82M
EBIT21.46M
Earnings Per Share (EPS)2.17

Balance Sheet

Q32 Bio Inc. holds 106.27M in cash and equivalents against 5.30M in total debt, resulting in a net debt position of -106.27M. Total book value stands at 105.91M, with working capital of 104.25M providing operational flexibility.

Cash & Cash Equivalents106.27M
Total Debt5.30M
Net Debt-106.27M
Equity (Book Value)105.91M
Book Value Per Share4.46
Working Capital104.25M

Cash Flow

Q32 Bio Inc. produced -19.83M in operating cash flow over the past twelve months.

Operating Cash Flow-19.83M
Capital ExpendituresN/A
Free Cash Flow-19.83M
FCF Per Share-1.27

Margins

Q32 Bio Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 39.94 and net profit margin of 62.87 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin39.94
Pretax Margin62.87
Profit Margin62.87
EBITDA Margin40.60

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-21.25
FCF Yield-10.00

Stock Splits

Q32 Bio Inc.'s most recent stock split took place on March 26, 2024 with a 18:1 split ratio.

Last Split Date3/26/2024
Split Ratio18:1

Scores

Q32 Bio Inc. posts an Altman Z-Score of 17.69, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score17.69